Back to search results

Muscle Blood Flow Regulation in HFpEF

This study is looking at how exercise training affects muscle blood flow and exercise ability in people with Heart Failure with preserved Ejection Fraction (HFpEF). HFpEF is a type of heart failure where the heart pumps normally but doesn't fill properly. You might be able to join if you are 18 or older, have HFpEF (with an LVEF, or Left Ventricular Ejection Fraction, above 50%), and meet certain biomarker levels (BNP >200 pg/mL or NT-proBNP >400 pg/mL). Participants will undergo 8 weeks of exercise training. Researchers will measure changes in your 6-minute walk test distance and muscle blood flow after 8 weeks to see if the training is successful. The study aims to enroll 35 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 35 participants.
What's involved
Participants will undergo 8 weeks of exercise training.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at 8 weeks, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05115890

Muscle Blood Flow Regulation in HFpEF

Recruiting
NAAges 18+InterventionalBasic science
VA Office of Research and Development
~35 participants
Updated 2026-04-21 on ClinicalTrials.gov
What's tested:Exercise training

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Six-minute walk test
Measured over Change from baseline six-minute walk test distance at 8 weeks
+1 more outcome measured

Conditions

HFpEF

Explore related trials

Heart failure with normal ejection fractionNPPB wt AlleleN-Terminal Fragment Brain Natriuretic Protein

Where it's being run

1 sites across 1 states
Utah1

Study leadership

  • Kanokwan Bunsawat, PhD · PRINCIPAL_INVESTIGATOR · VA Salt Lake City Health Care System, Salt Lake City, UT

Who to contact

Kanokwan Bunsawat, PhD
[email protected]
(801) 582-1565 · ext. 1951
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older and able to give written informed consent
New York Heart Association (NYHA) functional class II or III
Left Ventricular Ejection Fraction (LVEF) \> 50%
Plasma Brain Natriuretic Peptide (BNP) \>200 pg/mL or NT-proBNP 400 pg/mL at enrollment

Exclusion

Prior EF of \<50%.
NYHA Class IV or HF that cannot be stabilized on optimized pharmacotherapy
Acute coronary syndrome, infiltrative cardiomyopathy, or myocarditis
Patients with HFpEF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction)
Orthopedic limitations that would prohibit knee-extensor exercise
Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT
Women who are pregnant or may become pregnant, but the typical age of female patients with HFpEF will be postmenopausal
Current smokers

What this trial measures

  • Six-minute walk testChange from baseline six-minute walk test distance at 8 weeks

    The six-minute walk test is used to measure distance covered during walking at a comfortable speed for six minutes

  • Muscle blood flowChange from baseline skeletal muscle blood flow at 8 weeks

    Muscle blood flow will be assessed non-invasively via Doppler ultrasound